BioCentury | Mar 25, 2020
Product Development

COVID-19 roundup: Emergency use of Moderna vaccine could come earlier than expected; plus ASCO goes virtual, Galapagos pauses filgotinib trials and more

The overarching news was negative for biopharma Tuesday, with a fresh round of companies announcing trial delays. But Moderna offered a rare ray of light, hinting that its vaccine could be available sooner than many...
BC Extra | Jun 26, 2019
Clinical News

June 25 Clinical Quick Takes: Minerva meets in insomnia; plus Aldeyra, Genkyotex and more

Minerva rises with insomnia data  Seltorexant (MIN-202) from Minerva Neurosciences Inc. (NASDAQ:NERV) met the primary endpoint of reducing Latency to Persistent Sleep (LPS) at night 1 vs. placebo (p≤0.001) in a Phase IIb trial to...
BC Extra | Mar 26, 2019
Clinical News

Aldeyra's allergic conjunctivitis therapy clears Phase III hurdle

Aldeyra shares rose $2.57 (36%) to $9.71 on Tuesday after the company said both doses of reproxalap (ADX-102) met the primary endpoint in the Phase III ALLEVIATE trial to treat allergic conjunctivitis. The small molecule...
BC Extra | Sep 28, 2018
Financial News

Aldeyra, Nightstar price follow-ons

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) and Nightstar Therapeutics plc (NASDAQ:NITE) each priced follow-ons Thursday, raising a total of about $144 million. Aldeyra raised $72.2 million through the sale of 5.3 million shares at $13.75 in a...
BC Week In Review | Sep 28, 2018
Clinical News

Aldeyra planning Phase III program for dry eye disease therapy

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) reported that reproxalap (ADX-102) significantly reduced ocular dryness and discomfort in a Phase IIb trial to treat dry eye disease. The company plans to start Phase III testing of the candidate...
BC Extra | Sep 26, 2018
Clinical News

Aldeyra planning Phase III program for dry eye disease therapy

Aldeyra Therapeutics Inc. (NASDAQ:ALDX) added $3.45 (35%) to $13.35 on Wednesday after reporting that reproxalap (ADX-102) significantly reduced ocular dryness and discomfort in a Phase IIb trial to treat dry eye disease. The company plans...
BC Innovations | Jan 6, 2017
Product R&D

Viral ambitions

  Meissa Vaccines Inc. is translating studies from an Emory University team into a pair of vaccine platforms to protect specific at-risk subpopulations from infections by two otherwise innocuous viruses, RSV and the common cold....
BC Innovations | Jan 3, 2017
Distillery Therapeutics

Infectious disease

INDICATION: Respiratory syncytial virus (RSV) Rat studies suggest a live attenuated RSV vaccine engineered to stably express the prefusion conformation of RSV F protein could help prevent RSV infection. The vaccine expressed an RSV F...
BC Week In Review | Aug 15, 2016
Clinical News

Topical NS2: Phase II data

A double-blind, U.S. Phase II trial in 12 Sjogren-Larsson syndrome patients with moderate to severe ichthyosis showed that once-daily 1% topical NS2 administered on a 4x10 inch area of skin for 2 months significantly improved...
BC Week In Review | Mar 7, 2016
Clinical News

NS2: Phase IIa data

Top-line data from a double-blind, Canadian Phase IIa trial in 100 patients with induced seasonal allergic conjunctivitis showed that 0.5% NS2 ophthalmic drops significantly reduced ocular itching and tearing vs. vehicle ophthalmic drops (p<0.05 for...
Items per page:
1 - 10 of 23